Axa
CLVS

Axa’s Clovis Oncology, Inc. CLVS Stock Holding History

Axa’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,600
Closed -$41.6K – 1247
2022
Q1 		$41.6K Sell
20,600
-380,700
-95% -$748K ﹤0.01% 1179
2021
Q4 		$1.09M Buy
+401,300
New +$1.48M ﹤0.01% 938
2021
Q1 		– Sell
-341,100
Closed -$1.64M – 1368
2020
Q4 		$1.64M Buy
341,100
+4,749
+1% +$24K 0.01% 886
2020
Q3 		$1.96M Sell
336,351
-12,549
-4% -$75.1K 0.01% 813
2020
Q2 		$2.35M Buy
+348,900
New +$2.64M 0.01% 787
2018
Q1 		– Sell
-15,700
Closed -$1.07M – 1436
2017
Q4 		$1.07M Sell
15,700
-19,700
-56% -$1.38M ﹤0.01% 985
2017
Q3 		$2.92M Buy
+35,400
New +$2.81M 0.01% 750
2016
Q1 		– Sell
-48,230
Closed -$1.69M – 1444
2015
Q4 		$1.69M Buy
48,230
+20,900
+76% +$1.35M 0.01% 810
2015
Q3 		$2.51M Buy
+27,330
New +$2.37M 0.01% 732
2015
Q1 		– Sell
-29,919
Closed -$1.68M – 1503
2014
Q4 		$1.68M Buy
29,919
+1,636
+6% +$86K 0.01% 839
2014
Q3 		$1.28M Sell
28,283
-182
-0.6% -$7.6K 0.01% 853
2014
Q2 		$1.18M Sell
28,465
-1,145
-4% -$59K ﹤0.01% 891
2014
Q1 		$2.05M Buy
29,610
+1,542
+5% +$113K 0.01% 764
2013
Q4 		$1.69M Buy
28,068
+1,396
+5% +$75.9K 0.01% 812
2013
Q3 		$1.62M Buy
+26,672
New +$1.89M 0.01% 785

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Axa's CLVS Position: Q2 2022 in Review

Axa sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 20,600 shares — an estimated $41.6K sold.

Axa first reported a position in CLVS in Q3 2013 and held it in 15 quarters. The position peaked at $2.92M in Q3 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • Axa reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • Axa sold 20,600 Clovis Oncology, Inc. shares in Q2 2022, an estimated $41.6K.
  • Axa first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 15 quarters.
  • Axa's Clovis Oncology, Inc. position peaked at $2.92M in Q3 2017.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.